Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00949988 · ClinicalTrials.gov registry record · Phase 1
A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00949988 is a Phase 1 study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 3 participants.
The verdict
NCT00949988, a Phase 1 study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is an open-label phase I/II study that will investigate the combination of dasatinib and rituximab therapy in patients with relapsed/refractory CLL. In phase I, eligible subjects will take either 100 mg or 140 mg of dasatinib daily along with rituximab on day 1 of each cycle for 6 cycles. In phase II, eligible subjects will all receive the same dose of dasatinib, as established in the phase I portion, along with rituximab on day 1 of each cycle for 6 cycles. The investigators hypothesize that the combination of dasatinib and rituximab will demonstrate efficacy in the treatment of patients with relapsed/refractory CLL.
Interventions
- DRUG Dasatinib and Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00949988
The ClinicalTrials.gov registry entry for NCT00949988 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dasatinib and Rituximab is the first listed.
NCT00949988 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00949988 about?
NCT00949988 is a clinical study titled "A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia". This is an open-label phase I/II study that will investigate the combination of dasatinib and rituximab therapy in patients with relapsed/refractory CLL. In phase I, eligible subjects will take either 100 mg or 140 mg of dasatinib daily along with rituximab on day 1 of each cycle for 6 cycles. In ph...
What is the current status of trial NCT00949988?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2009-05. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00949988?
The interventions under investigation include: Dasatinib and Rituximab (DRUG).
Who is sponsoring clinical trial NCT00949988?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.